Category - News

Markets

Leerink resumes coverage of Innate Pharma at OP; PT €9

Leerink resumed coverage of Innate Pharma (Euronext Paris: FR0010331421 – IPH) with an “outperform” rating and price target of €9. The stock closed at €5.28 on June 13. Innate is developing therapeutic antibodies that...

June 14, 2018

Markets

Ladenburg cuts Flex Pharma to neutral, drops PT

Ladenburg Thalmann downgraded Flex Pharm (NASDAQ:FLKS) to “neutral” from “buy” without a price target after the company halted two Phase 2 trials. In afternoon trading on June 13, shares of Flex were quoted at $1.36...

June 13, 2018

Developments

Ortho RTi posts positive rotator cuff repair data

Ortho Regenerative Technologies (CSE:ORTH) reported positive outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries. Conducted by researchers from Montreal’s École...

June 13, 2018

Markets

Mackie starts Aleafia Health at buy; PT $1.75

Mackie Research initiated coverage of Aleafia Health (TSXV:ALEF) with a “buy” rating and price target of $1.75. The stock closed at 51 cents on June 12. Aleafia runs the largest network of referral-only medical cannabis...

June 13, 2018

Markets

Roth starts Stemline Therapeutics at buy; PT $30

Roth Capital Partners initiated coverage of Stemline Therapeutics (NASDAQ:STML) with a “buy” rating and $30 price target. The stock closed at $17.90 on June 11. “We expect Stemline to sail smoothly through a biologics...

June 12, 2018

Markets

Canaccord ups Tactile Systems PT to $56

Canaccord Genuity raised its price target for Tactile Systems Technology (NASDAQ:TCMD) to $56 from $46 on the heels of a recent acquisition of IP. The stock closed at $51.37 on June 11. Tactile is a medical device...

June 12, 2018

Markets

HCW starts Tocagen at buy; PT $14.50

H.C. Wainwright initiated coverage of Tocagen (NASDAQ:TOCA) with a “buy” rating and price target of $14.50. The stock closed at $9.64 on June 8. Analyst Swayampakula Ramakanth writes that the company’s lead product...

June 11, 2018

Markets

Roth resumes coverage of LeMaitre Vascular at buy; PT $38

Roth Capital Partners resumed coverage of LeMaitre Vascular (NASDAQ:LMAT) with a “buy” rating and $38 price target. The stock closed at $33.77 on June 7. LeMaitre offers disposable medical devices, implants (synthetic...

June 8, 2018

Markets

HCW starts Axsome Therapeutics at buy; PT $10

H.C. Wainwright initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with a “buy” rating and price target of $10. The stock closed at $3.60 on June 6. Axsome, which is focused on central nervous system (CNS)...

June 7, 2018

Markets

Ladenburg starts Marinus Pharma at buy; PT $20

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5. Marinus is developing ganaxolone (GNX), a synthetic analog of...

June 6, 2018

Category - News

Subscribe